IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0310880.html
   My bibliography  Save this article

Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019

Author

Listed:
  • Yudai Kaneda
  • Erika Yamashita
  • Hiroaki Saito
  • Kenji Gonda
  • Masahiro Wada
  • Tetsuya Tanimoto
  • Akihiko Ozaki

Abstract

Introduction: The introduction of new drugs often leads to aggressive promotion and potential financial conflicts of interest, which may bias treatment decisions and potentially harm patients. The breast cancer therapeutics market is rapidly evolving globally, and Japan is no exception. This study aimed to analyze trends in pharmaceutical payments to breast cancer specialists in Japan from 2016 to 2019, focusing on company-level data, relationships with new drug introductions, and individual specialist payment patterns. Methods: This retrospective study examined financial relationships between pharmaceutical companies and breast cancer specialists in Japan from 2016 to 2019. The analysis focused on certified specialists as of May 2023 and used payment data from 93 pharmaceutical companies for activities such as lecturing, writing, and consulting. First, a company-level analysis examined total payments, categories, and trends for all companies and the top 10 individually; second, a specialist-level analysis looked at payment amounts amount and counts. The Gini index was employed to assess the concentration of payments among specialists. Results: Total payments reached USD 13,329,911, growing at 10.1% annually, with 81.4% allocated to lecturing engagements. The top 10 companies, led by Chugai Pharmaceutical, Eisai, and AstraZeneca, accounted for 89.5% of all payments. Companies like Pfizer Japan and Eli Lilly Japan saw notable increases following the introduction of new drugs such as palbociclib and abemaciclib. Payment distribution was highly skewed, with an average of $7,692 per specialist but a median of only $2,884. A Gini index of 0.994 further confirmed that a small group of specialists received a disproportionately large share of the payments Conclusion: From 2016 to 2019, pharmaceutical payments to Japanese breast cancer specialists increased significantly, coinciding with new drug introductions. The concentration of payments among a select group of specialists raises concerns about potential influences on clinical decision-making and guideline recommendations.

Suggested Citation

  • Yudai Kaneda & Erika Yamashita & Hiroaki Saito & Kenji Gonda & Masahiro Wada & Tetsuya Tanimoto & Akihiko Ozaki, 2024. "Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019," PLOS ONE, Public Library of Science, vol. 19(9), pages 1-15, September.
    • Handle: RePEc:plo:pone00:0310880
    DOI: 10.1371/journal.pone.0310880
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0310880
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0310880&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0310880?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Genevieve Pham-Kanter, 2014. "Act II of the Sunshine Act," PLOS Medicine, Public Library of Science, vol. 11(11), pages 1-3, November.
    2. Ozaki, Akihiko & Saito, Hiroaki & Senoo, Yuki & Sawano, Toyoaki & Shimada, Yuki & Kobashi, Yurie & Yamamoto, Kana & Suzuki, Yosuke & Tanimoto, Tetsuya, 2020. "Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016," Health Policy, Elsevier, vol. 124(7), pages 727-735.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anju Murayama & Yuki Senoo & Kayo Harada & Yasuhiro Kotera & Hiroaki Saito & Toyoaki Sawano & Yosuke Suzuki & Tetsuya Tanimoto & Akihiko Ozaki, 2022. "Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians," IJERPH, MDPI, vol. 19(6), pages 1-24, March.
    2. Anju Murayama & Sae Kamamoto & Hiroaki Saito & Kohki Yamada & Divya Bhandari & Iori Shoji & Hanano Mamada & Moe Kawashima & Erika Yamashita & Eiji Kusumi & Toyoaki Sawano & Binaya Sapkota & Tetsuya Ta, 2022. "Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019," IJERPH, MDPI, vol. 19(12), pages 1-13, June.
    3. Moriarty, Frank & Larkin, James & Fahey, Tom, 2021. "Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study," Health Policy, Elsevier, vol. 125(10), pages 1297-1304.
    4. Harada, Kayo & Ozaki, Akihiko & Saito, Hiroaki & Sawano, Toyoaki & Yamamoto, Kana & Murayama, Anju & Senoo, Yuki & Tanimoto, Tetsuya, 2021. "Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017," Health Policy, Elsevier, vol. 125(3), pages 320-326.
    5. Mulinari, Shai & Martinon, Luc & Jachiet, Pierre-Alain & Ozieranski, Piotr, 2021. "Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries," Health Policy, Elsevier, vol. 125(7), pages 915-922.
    6. Larkin, James & Matthes, Britta & Azribi, Mohamed & Kearns, Conor & Mulinari, Shai & Rickard, Emily & Moriarty, Frank & Fahey, Tom & Ozieranski, Piotr, 2024. "Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysis," Health Policy, Elsevier, vol. 149(C).
    7. Rose, Susannah L. & Sah, Sunita & Dweik, Raed & Schmidt, Cory & Mercer, MaryBeth & Mitchum, Ariane & Kattan, Michael & Karafa, Matthew & Robertson, Christopher, 2021. "Patient responses to physician disclosures of industry conflicts of interest: A randomized field experiment," Organizational Behavior and Human Decision Processes, Elsevier, vol. 166(C), pages 27-38.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0310880. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.